Skip to main content

Drug Interactions between bcg vaccine and rifapentine

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

rifapentine BCG vaccine

Applies to: rifapentine and bcg vaccine

Consumer information for this interaction is not currently available.

GENERALLY AVOID: Coadministration of antituberculosis drugs with the BCG vaccine may result in an inadequate immune response to the vaccine. The exact mechanism has not been described but it is likely that BCG vaccine, which contains a live, attenuated culture of Bacillus of Calmette and Guerin strain of Mycobacterium bovis, is sensitive to the antituberculosis effects of these drugs. Available data suggests that BCG vaccine is sensitive to commonly used antituberculosis agents such as isoniazid, ethambutol, and rifampin; it is reportedly not sensitive to pyrazinamide. However, clinical and/or sensitivity data are not available for BCG vaccine and all antituberculosis agents.

MANAGEMENT: Due to the potential loss of vaccine efficacy, the manufacturer recommends that concomitant use of antituberculosis drugs with the BCG vaccine should generally be avoided. However, in cases of accidental BCG overdosage, immediate treatment with antituberculosis drugs is recommended. In addition, if a systemic BCG infection is suspected after administration of the vaccine, antituberculosis therapy should be initiated and an infectious disease expert consulted for further guidance.

References

  1. "Product Information. BCG Vaccine AJV (BCG vaccine)." AJ Vaccines (2019):
  2. "Product Information. BCG Vaccine (BCG vaccine)." Merck Sharp & Dohme LLC (2023):
  3. Durek C, Rusch-Gerdes S, Jocham D, Bohle A "Sensitivity of BCG to modern antibiotics https://pubmed.ncbi.nlm.nih.gov/10575268/" (2024):

Drug and food interactions

Moderate

rifapentine food

Applies to: rifapentine

Consumer information for this interaction is not currently available.

ADJUST DOSING INTERVAL: Administration with food may increase the oral bioavailability of rifapentine and reduce the incidence of gastrointestinal adverse events. Administration with a high fat meal typically increases rifapentine's maximum concentration (Cmax) and systemic exposure (AUC) by approximately 40% to 50% over that observed when rifapentine is administered under fasting conditions. Rifapentine is often prescribed in combination with isoniazid. When single doses of rifapentine (900 mg) and isoniazid (900 mg) were administered with a low fat, high carbohydrate breakfast, the Cmax and AUC of rifapentine increased by 47% and 51%, respectively. On the other hand, isoniazid's Cmax and AUC decreased by 46% and 23%, respectively.

MANAGEMENT: Products containing oral rifapentine as the sole ingredient recommend administration with a meal to increase bioavailability and reduce the occurrence of gastrointestinal upset, nausea, and/or vomiting. Consultation of product labeling for combination products and/or relevant guidelines may be helpful if rifapentine is combined with a medication that is typically taken on an empty stomach.

References

  1. "Product Information. Isoniazid/Rifapentine 300 mg/300 mg (Macleods) (isoniazid-rifapentine)." Imported (India) 2 (2021):
  2. "Product Information. Priftin (rifapentine)." sanofi-aventis (2021):

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer